Background: Chronic Lymphocytic Leukemia (CLL) is the most common chronic lympho-proliferative disorder. This study was done to explore the frequency of serum Immunoglobulin (Ig) paraprotein in patients with CLL and its correlation with other prognostic factors as expression of CD38 and zeta-chain-associated protein kinase 70 (ZAP70) on malignant lymphocytes.
Introduction
CHRONIC Lymphocytic Leukemia (CLL) is a monoclonal expansion of small mature B lymphocytes accumulating in the peripheral blood, bone marrow, and lymphoid organs. CLL is one of the most common types of leukemia in the Western world, however, infrequent in the Eastern. It is the most common types of leukemia diagnosed in adult [1] . CLL cells are positive for monotypic surface immunoglobulin (dim intensity), CD5, CD19, CD20 (dim intensity) and CD23 and usually negative for CD22, CD79b and FMC-7 [2] .
The limitation of clinical staging systems (Rai and Binet staging systems) in CLL, which fail to identify early-stage patients who most likely to progress, has led to the search for new prognostic markers with highly predictive capabilities like thymidine kinase, beta2-microglobulin (B2-M), CD38, zeta-chain-associated protein kinase 70 (ZAP70) and detection of monoclonal gamopathy [3] .
Expression of CD38 on CLL cells has been
shown to be increased in more proliferative clones. There is a close association between CD38 expression and increased Ki-67 proliferation index along with increased ZAP70 positivity [4] .
Serum immunoglobulin paraprotein can be detected in a subset of patients with CLL by Serum Protein Electrophoresis (SPE) and immunofixation electrophoresis (IFE). The World Health Organization (WHO) classification recognizes that a "small M component" can be found in some patients with CLL, but no mention is made about the fre-389 390 Serum Immunoglobulin Paraprotein in Patients with CLL quency of this occurrence or the range of serum paraprotein levels in patients with CLL. An earlier study reported that patients with CLL with Immunoglobulin (Ig) paraproteinemia had an inferior survival compared with patients with CLL without serum paraprotein. However, other studies have not confirmed this observation. Therefore, how does the serum Ig paraprotein actually affect the CLL patients' survival is still unknown [5] .
Patients and Methods
The study was done on 30 CLL patients and 20 sex and age matched control. Those patients were presented to South Egypt Cancer Institute Assiut University Hospital in the period between December 2014 and May 2016. The study was approved by the Institutional Review Board of Faculty of Medicine, Assiut University. An informed written consent was taken from of all cases and controls.
All patients and controls were subjected to: • Thorough history taking and clinical examination, with careful assessment of clinical signs relevant to leukemia as hepatomegaly, splenomegaly, lymphadenopathy.
• Complete blood picture were performed by the fully automated blood counters Ruby Cell Dyn (American, Serial number: 36026BG) and Cell Dyn 1700 (American, Serial number: 513554). Blood Films were stained with Leishman stain, and were used for morphological identification of the differential count.
• Liver function tests, kidney function tests and estimation of LDH were performed by Cobas integra 400 plus (Swiss, Serial number: 500558).
• Bone marrow examination.
• Immunophenotyping analysis was done by multicolor flow cytometry (FACSCaliber, BD Biosciences-San Jose, CA, USA, serial number E5140). Foreward scatter and side scatter histogram were made to detect the lymphocyte population. Lymphocytes were then gated for further analysis of different monoclonal antibodies as CD5, CD10, CD19, κappa, lamda, FMC7, CD23, CD3, CD38 and Zap70.
Immunophenotyping diagnosis of our CLL patients was done according to scoring system [6] .
• Serum protein electrophoresis and acid blue immunofixation: Serum sample were collected and stored in -20ºC until analysis. SPE was used as a screening test, while IFE was for confirmation and isotype identification. Pretty Interlab protein electrophoresis analyser (Italy, serial number 38405301) automatically performed all the steps of the analytical procedure in SPE: After application of the samples on the agarose gel plate, electrophoretic migration, gel denaturation, gel staining and de-staining and final gel drying were done.
Immunofixation was done after the electrophoretic migration by application of the fixative solution and the antisera, gel incubation at 20ºC and gel blotting at 40ºC.
Statistical analysis:
Statistical analysis was carried out using SPSS statistical software Version 18. Qualitative data are expressed frequency and percentage; quantitative data are expressed by mean ± Standard Deviation of mean (SD). Comparisons between variables were performed using the chi-square test and independent samples t-test. p-value <0.05 was considered significant.
Results

Fig.
(1) shows the distribution of CLL patients according to modified Rai staging system. Table (1) show the base line characteristic of CLL patients and the controls.
The expression of CD38 on malignant lymphocytes was detected in 15 patients (50%) with mean expression of 64.84 ± 23.60. However, the expression of ZAP70 on malignant lymphocytes was detected only in 7 patients (23.3%) with mean expression of 57.98 ±23.43 as in Fig. (2) .
In the present study, 4 CLL patients (13.4%) had monoclonal gammopathy (M-band), the type of M-band in the 4 patients was IgG-Kappa Figs. (3, 4) . One patient (3.3%) had diffuse band (polyclonal gammopathy).
There was significant relation between presence of immunoglobulin paraprotein in CLL patients and ZAP 70 expression with p-value=0.034. On the other hand there was no significant relation between presence of M-band in CLL patients and CD38 expression. Also there was no significant relation between modified Rai staging system and the presence of M-band as shown in Tables (2, 3) .
Low risk
10.0% Fig. (1) 
Discussion
Although M-protein secretion is typically a feature of plasma cell dyscrasias, monoclonal gammopathy has been recognized in a wide variety of lymphoproliferative disorders. It has been described in patients with B-CLL, well-differentiated lymphoma, Burkitt's lymphoma and other histological subtypes of lymphomas [2] .
The expression of ZAP 70 on malignant lymphocytes was detected in 23.3% of our CLL patients. This result is near the result found by Morabito et al., who reported that ZAP-70 was positive expressed in 34.9% of all studied CLL cases [7] . Also, Del Principe et al., found that ZAP-70 was positive expressed in 36% of all CLL cases [8] . Otherwise, other study done by Cruse et al., and found that ZAP-70 expression was positive in (64.7%) of CLL cases [9] . In contrast, Deaglio et al., reported that ZAP-70 expression was positive in (9.52%) of their studied CLL patients [10] . This variation in the expression of ZAP-70 in CLL patients between our results and previous studies may be due to the low number of our studied patients and also indicate that more large study is required.
Regarding CD38 expression, 50% of our CLL patients were CD38 positive. This result was nearly in agreement with Cruse et al., [9] and Del Principe et al., [8] studies, who found that the expression of CD38 was detected in (40%) and (36%) respectively, of their CLL cases. In addition to, Deaglio et al., found that CD38 expression was detected in (58.92%) of his studied cases [10] . In contrast, only (19.5%) of cases were positive for CD38 expression in Morabito et al., study [7] .
In the present study only 4 patients (13.4%) had monoclonal gamopathy (M-band), the type of the M-band in these patients was IgG-Kappa (100%). One patient had diffuse band (3.3%). This result is in agreement with Xu et al., [5] who study the prognostic significance of serum immunoglobulin paraprotein in patients with CLL. His study was conducted on 133 consecutive patients with newly diagnosed CLL. Serum immunoglobulins were measured by SPE and IFE. They identified 27 patients with immunoglobulin paraproteinemia from a total of 133 untreated patients with CLL, with a frequency of 20.3%.
Yin and his colleagues [11] examined the sera of 1,053 untreated patients with CLL/SLL by SPE and IFE. They identified 26 IgM paraprotein with a frequency of (2.47%). Yin concluded that all CLL/SLL patients in his study had relatively low levels of serum monoclonal IgM.
Noel et al., reviewed the records of all Mayo
Clinic patients seen between January 1971 and July 1984 and found that one hundred patients with CLL and a monoclonal protein in serum or urine were recognized during this period. They reported that IgG monoclonal proteins predominated in CLL patients with the following distribution: IgG kappa 36%, IgG lambda 15%, IgM kappa 27%, IgM lambda 11%, IgA lambda 1%, and free monoclonal light chains in 10% (kappa in 8% and lambda in 2%) [12] . Also Xu et al., identified 27 patients with Ig paraproteinemia (12 patients with IgG paraprotein, 12 patients with IgM paraprotein, 3 patients with both IgG and IgM) from a total of 133 untreated patients with CLL [5] .
Guastafierro et al., recorded that in their study on CLL patients, one patient had lambda FLC and IgG lambda simulating a biclonal gammopathy [14] . Also Sanchez et al., suggested that these additional M components may represent biclonal or triclonal lymphoproliferative disorders or the development of a subclone within the original tumor cells because of clonal evolution [13] . The possible explanations of discrepancy in frequency of serum immunoglobulin paraprotein in CLL patients and their prognostic impact might be due to different therapeutic regimens, shorter clinical follow-up and smaller number of patients.
In this study, we found a significant relation between presence of M-band by protein electrophoresis and ZAP 70 positivity. This may indicate that the detection of immunoglobulin paraprotein may be added as a prognostic factor in CLL. Our results is in agreement with Xu et al., who suggested the possibility of interaction between serum immunoglobulin paraprotein and other known prognostic factors, such as serum level of B2-M, LDH, ZAP-70 [5] .
